FDA Brief

Warning letters Drugs

FDA warning letter to

TCI Co., Ltd BioCosme PABP BRANCH

High riskIssued Sep 2Posted Oct 6Center for Drug Evaluation and Research (CDER)

FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.

What happened

FDA inspected TCI Co., Ltd. - BioCosme PABP BRANCH in Pingtung County, Taiwan, from March 9 to March 13, 2026, and found significant CGMP (current good manufacturing practice) violations for over-the-counter drugs. FDA said the firm released OTC drug batches without required active-ingredient strength testing, lacked identity testing for incoming components, did not adequately validate its processes, and had weak quality-unit oversight. FDA reviewed the firm's April 2, 2026, response and found it inadequate because it lacked supporting documentation or adequate evidence of corrective actions.

What FDA found

  1. The company released OTC drug batches without testing the active ingredient's identity and strength before release.

    21 CFR 211.165(a)
  2. The company did not test incoming ingredients for identity and purity and did not verify suppliers' certificates of analysis at appropriate intervals.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The company lacked adequate written procedures for production and process controls and did not properly validate its OTC drug manufacturing processes or qualify a component used in manufacturing and cleaning.

    21 CFR 211.100(a)
  4. The quality control unit did not ensure compliance, allowed process changes without required change control, had incomplete batch records, and had no written stability testing program.

    21 CFR 211.22; 21 CFR 211.188(b); 21 CFR 211.166(a)

What FDA wants

FDA asks the company to respond in writing within 15 business days to CDER-OC-OMQ-Communications@fda.hhs.gov with corrective action documentation and plans covering quality agreements, testing, validation, and quality-unit oversight. If the company resumes drug manufacturing, it must notify FDA before resuming and should use a qualified consultant for a six-system CGMP audit.

Who should pay attention

  • brands that buy OTC drug products from this contract manufacturer
  • U.S. distributors and retailers of its OTC drugs
  • quality teams managing supplier qualification and quality agreements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk